explore -WSS

explore

author：fashion 2025-10-02 23:30:51 - browse：31616

Daniel M. Skovronsky on stage at the 2023 STAT Summit. — Dan Skovronsky, Eli Lilly's chief scientific officer, at the 2023 STAT Summit. STAT

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels of Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts.

But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance. Why? Because researchers were presenting data on the ability of Novo Nordisk’s obesity drug Wegovy to prevent heart attacks, strokes, and deaths in people with overweight who have established cardiovascular disease. That has big implications for the market for Lilly’s own obesity drug, Zepbound, which was approved by the Food and Drug Administration last week, and for the company’s future efforts in obesity.

STAT sat down with Lilly’s chief scientific officer, Dan Skovronsky, at the AHA meeting to talk about the obesity drugs known as GLP-1s, the new Lp(a) drug, and the company’s partnership with the gene editing firm Verve. An edited transcript of the conversation follows.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： How to save health care price transparency rules

hotspot

WSS

John Green on his newest strategy for fighting tuberculosis

Senate bill would ban some hospital facility fees

John Green on his newest strategy for fighting tuberculosis

Amid AI frenzy, a top HHS official's quest to create safeguards

Neurocrine congenital adrenal hyperplasia trial succeeds

FDA weighs limits of animal data in assessing artificial wombs

leisure time

explore

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

How to save health care price transparency rules

Hepatitis C has a cure — but many Americans still lack access to it

Midwives could help bridge maternal health disparities in the U.S.

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Dobbs anniversary: the lost opportunity of abortion as health care

RaDonda Vaught links Vanderbilt hospital issues to patient death

Duchenne breakthrough therapy leaves behind pioneering families

How many hemophilia patients actually want gene therapy?

Wikipedia

How to save health care price transparency rules

'A game

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

EPA limits use of carcinogenic gas for sterilizing medical devices

Why the drug industry's warnings on the IRA's impact fall short

Midwives could help bridge maternal health disparities in the U.S.

leisure time

knowledge

hotspot

focus